PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells

Journal of Molecular Neuroscience

Volumn 48, Issue 3, 2012, Pages 660-666

  Moody, Terry W ^a   Di Florio, Alessia ^b   Jensen, Robert T ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

PACAP; PYK 2; Signal transduction; Tyrosine phosphorylation

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; CALCIUM ION; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; PAXILLIN;

ARTICLE; CANCER CELL; LUNG NON SMALL CELL CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CALCIUM SIGNALING; CELL LINE, TUMOR; CHELATING AGENTS; CYTOSOL; EGTAZIC ACID; ESTRENES; FOCAL ADHESION KINASE 2; HUMANS; ISOQUINOLINES; LUNG NEOPLASMS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PHOSPHOTYROSINE; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRROLIDINONES; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; SULFONAMIDES;

EID: 84868212664     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-012-9785-6     Document Type: Article

References (36)

1. Bellis SL, Perotta JA, Curtis MS, Turner CE (1997) Adhesion of fibroblasts to fibronectin stimulates both serine and tyrosine phosphorylation of paxillin. Biochem J 325:375-381 (Pubitemid 27338716)
2. Calaib MB, Polte TR, Hanks SK (1995) Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity. Mol Cell Biol 15:954-963
3. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J (1996) A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 383:547-550 (Pubitemid 26346184)
4. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK (2007) Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67:10976-10983 (Pubitemid 350145927)
5. Hall JE, Fu W, Schaller MD (2011) Focal adhesion kinase: exploring FAK structure to gain insight into function. Int Rev Cell Mol Biol 288:185-225
6. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811-819
7. Kuwabara K, Nakaoka T, Sato K, Nishishita T, Sasaki T, Yamashita N (2004) Differential regulation of cell migration and proliferation through proline-rich tyrosine kinase 2 in endothelial cells. Endocrinology 145:3324-3330 (Pubitemid 38830004)
8. LeeM, Jensen RT, Bepler G, Korman LY,Moody TW (1990) Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cAMP" levels. Peptides 11:1205-1210
9. Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B, Schlessinger JA (1995) Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature 376:737-745
10. Lipinski CA, Loftus JC (2010) Targeting Pyk2 for therapeutic intervention. Expert Opin Ther Targets 14:95-108
11. Lipinski CA, Tran NL, Menashi E, Rohl C, Kloss J, Bay RC, Berens ME, Loftus JC (2005) The tyrosine kinase PYK2 promotes migration and invasion of glioma cells. Neoplasia 7:435-445 (Pubitemid 40791863)
12. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, deGroot J, Yung WK (2007) Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 6:1357-1367 (Pubitemid 46711999)
13. Lutz EM, Sheward WJ, West KM, Morrow JA, Harmar AJ (1993) The VIP2 receptor molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334:3- 8
14. May V, Lutz E, MacKenzie C, Schutz K, Dozark K, Braas K (2010) Pituitary adenylate cyclase-activating polypeptide (PACAP)/ PAC1HOP1 receptor activation coordinates multiple neurotophic signaling pathways. J Biol Chem 285:9749-9761
15. Moody TW, Jensen RT (2006) VIP and PACAP as autocrine growth factors in breast and lung cancer. In: Kastin A (ed) Handbook of biologically active peptides. Elsevier, Amsterdam, pp 493-498
16. Moody TW, Leyton J, Chan D, Brenneman DC, Fridkin M, Gelber E, Levy A, Gozes I (2001) VIP receptor antagonists potentiate the action of chemotherapeutic drugs on breast cancer cells. Breast Cancer Res Treat 68:55-64 (Pubitemid 32928271)
17. Moody TW, Leyton J, Casibang M, Pisegna J, Jensen RT (2002) PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Regul Pept 109:135-140
18. Moody TW, Chan D, Fahrenkrug J, Jensen RT (2003a) Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 9:495-509 (Pubitemid 36131740)
19. Moody TW, Hill JM, Jensen RT (2003b) VIP as a trophic factor in the CNS and cancer cells. Peptides 24:163-177 (Pubitemid 36165188)
20. Moody TW, Leyton J, Jensen RT (2012a) Pituitary adenylate cyclaseactivating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin. J Mol Neurosci 46:68-74
21. Moody TW, Osefo N, Nuche-Berenguer B, Ridnour L,Wink D, Jensen RT (2012b) Pituitary adenylate cyclase activating polypeptide causes tyrosine phosphorylation of the EGF receptor in lung cancer cells. J Pharm Exp Ther [Epub ahead of print]
22. Pace A, Garcia-Marin LJ, Tapia JA, Bragado MJ, Jensen RT (2003) Phosphospecific site tyrosine phosphorylation of p125FAK and proline-rich kinase 2 is differentially regulated by cholecystokinin receptor type A activation in pancreatic acini. J Biol Chem 278:19008-19016 (Pubitemid 36799285)
23. Picascia A, Stanzione R, Chieffi P, Kisslinger A, Dikic I, Tramontano D (2002) Proline-rich tyrosine kinase 2 regulates proliferation and differentiation of prostate cells. Mol Cell Endocrinol 186:81-87 (Pubitemid 34189781)
24. Pisegna J,Wank SA (1993) Molecular cloning and functional expression of the pituitary adenylate cyclase activating polypeptide type I receptor. Proc Natl Acad Sci USA 90:6345-6349
25. Pisegna JR, Wank SA (1996) Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J Biol Chem 271:17267-17274 (Pubitemid 26244284)
26. Reubi JC, Laderach U, Waser B, Gebbers JD, Robberecht P, Laissue JA (2000) Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60:3105-3112 (Pubitemid 30395841)
27. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, Coleman K, Yao L, Martinez-Alsina L, Lorenzen M, Berliner M, Luzzio M, Patel N, Schmitt E, LaGreca S, Jani J, Wessel M, Marr E, Griffor M, Vasdos F (2008) Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68:1935-1944 (Pubitemid 351416580)
28. Rolle S, Grosse R, Buech T, Chubanov V, Gudermann T (2008) Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells. Oncogene 27:1737-1748 (Pubitemid 351380271)
29. Schaller MD, Borgman CA, Cobb BS, Vaines RR, Reynolds AB, Parsons JT (1992) P125FAK, a structurally distinctive protein tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 89:192-196
30. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N,Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site blinded validation study. Nat Med 14:822-827
31. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365:170-175 (Pubitemid 23282064)
32. Tapia JA, Ferris HA, Jensen RT, Garcia LJ (1999) Cholecystokinin activates PYK2/CAKβ by a phospholipase C-dependent mechanism and its association with the mitogen-activated protein kinase signaling pathway in pancreatic acinar cells. J Biol Chem 274:31261-31271
33. Wittau N, Grosse R, Kalkbrenner F, Gohla A, Schultz G, Gudermann T (2000) The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to Gq, Gi and G12 proteins. Oncogene 19:1318-1328
34. Zhang S, Qiu X, Gu Y, Wang E (2008) Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer. Lung Cancer 62:295-301
35. Zia F, Fagarasan M, Bitar K, Coy DH, Pisegna J, Wank S, Moody TW (1995) PACAP receptors regulate the growth of non-small cell lung cancer cells. Cancer Res 55:4886-4891
36. Zrihan-Licht S, Fu Y, Settleman J, Schinkmann K, Shaw L, Keydar I, Avraham S, Avraham H (2000) RAFTK/PYK2 tyrosine kinase mediates the association of P190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene 19:1318-28 (Pubitemid 30160624)